Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
RNA Targeting Small Molecule Drug Discovery Market Size Forecast: How Big Could The Market Get By 2030?
The rna targeting small molecule drug discovery market has experienced substantial expansion in recent years. It will grow from $2.13 billion in 2025 to $2.6 billion in 2026 at a compound annual growth rate (CAGR) of 22.3%. The historical increase in this market can be attributed to several factors, including the limited druggability of protein targets, an escalating prevalence of genetic disorders, advancements in rna biology research, increased academic-industry collaborations, and the early successes of rna-based therapeutics.
The rna targeting small molecule drug discovery market size is projected to experience rapid expansion in the coming years. This market is anticipated to reach $6.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.5%. Factors driving this growth during the forecast period include the advent of AI-enabled rna target identification, a rise in precision medicine investments, the broadening of rna therapeutics pipelines, advancements in rna delivery technologies, and favorable regulatory backing for new treatment approaches. Key trends expected within the forecast timeframe encompass AI-powered rna structure prediction, an increase in rna-targeted oncology pipelines, progress in rna-specific small molecule libraries, enhanced rna binding selectivity and specificity, and the incorporation of multi-omics into rna drug discovery processes.
Get A Free Sample Report With In-Depth Market Insights:
RNA Targeting Small Molecule Drug Discovery Market Demand Drivers: What’s Powering Industry Growth?
The RNA-targeted small-molecule drug discovery market is projected to grow due to the increasing occurrence of cancer, genetic disorders, and viral infections. Cancer is defined as a collection of diseases characterized by the uncontrolled multiplication of cells within the body. Viral infections pertain to illnesses caused by viruses, which are microscopic infectious agents capable of replicating only inside the living cells of organisms. RNA targeting-based drug discovery offers a method to treat cancer, genetic disorders, and viral infections, as these conditions are associated with genes and impaired genetic material, which can be addressed by drugs developed using RNA targeting-based approaches. For instance, in February 2024, a report from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, revealed an estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most prevalent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, new cancer cases are anticipated to climb by 77%, reaching over 35 million annually. Thus, the rising prevalence of cancer, genetic disorders, and viral infections is a key driver for the growth of the RNA-targeted small-molecule drug discovery market.
RNA Targeting Small Molecule Drug Discovery Market Breakdown By Product Type And Application
The rna targeting small molecule drug discovery market covered in this report is segmented –
1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications
Subsegments:
1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition
2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA
3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways
4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA
RNA Targeting Small Molecule Drug Discovery Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies in the RNA-targeting small-molecule drug discovery market are implementing innovative platforms, including software-as-a-service platforms, to gain a competitive edge. Software-as-a-service (SaaS) is defined as a software distribution model where applications are hosted by a third-party vendor and are accessible to customers via the Internet. For example, in December 2023, the US-based science and technology company Merck & Co. Inc. launched AIDDISON. This platform suggests optimal synthesis routes for selected medications. This novel approach has the potential to generate significant cost savings in the drug discovery process and markedly improve the success rate for introducing new medicines to patients. By bridging the divide between virtual molecular design and real-world manufacturability, the platform elevates the success rate of delivering innovative treatments to patients by extracting crucial insights from vast datasets. This advanced AI system integrates computer-aided drug design, machine learning, and generative AI to expedite the medication development timeline.
RNA Targeting Small Molecule Drug Discovery Market Company Landscape And Competitive Strategy
Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation
View The Full RNA Targeting Small Molecule Drug Discovery Market Report:
RNA Targeting Small Molecule Drug Discovery Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model